Vimta Labs Limited has informed the Exchange regarding Appointment of Dr Yadagiri R Pendri as Non- Executive Independent Director of the company w.e.f. August 10, 2025.
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs has informed the exchanges that shareholders at the 35th Annual General Meeting held on June 6, 2025 approved the re-appointment of Dr. Yadagiri R Pendri (DIN: 01966100) as a Non-Executive Independent Director. This is his second and final term, lasting five years from August 10, 2025 to August 9, 2030. Dr. Pendri brings over 35 years of pharmaceutical R&D experience, is the founder and CEO of Escientia Lifesciences, a CDMO company, and holds a Ph.D. from the National Chemical Laboratory, Pune. He previously held leadership roles at Bristol-Myers Squibb in the USA and has over 15 US patents to his name. He is not related to any existing director and holds no shares in the company.
This is a routine governance announcement with no material impact on the stock. Continuity of an experienced independent director with strong pharma R&D credentials is broadly positive for board quality, particularly given Vimta Labs' life sciences focus.